1369256-35-8

Basic information

• Product Name: (3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol
• Synonyms: (3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol
• CAS NO: 1369256-35-8
• Molecular Weight: 287.214
• Mol File: 1369256-35-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(1369256-35-8)
• EPA Substance Registry System: (3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(1369256-35-8)

Safety Data

• Hazardous Substances Data: 1369256-35-8(Hazardous Substances Data)

Upstream product

• 216766-12-0 5-hydroxy-2-trifluoromethyl pyridine 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 1369256-33-6 3-fluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)benzaldehyde 

Downstream Products

• 1420368-06-4 8-((3-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-1-isopropyl-3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one 
• 1620678-75-2 8-((3-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-2-methyl-3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one 

Relevant articles and documents

Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof

The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

BICYCLIC PYRIMIDONE COMPOUNDS

The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.